1. Home
  2. IMNM vs IVT Comparison

IMNM vs IVT Comparison

Compare IMNM & IVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$28.01

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo InvenTrust Properties Corp.

IVT

InvenTrust Properties Corp.

HOLD

Current Price

$32.82

Market Cap

2.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
IVT
Founded
2006
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
IMNM
IVT
Price
$28.01
$32.82
Analyst Decision
Strong Buy
Buy
Analyst Count
10
7
Target Price
$32.80
$32.50
AVG Volume (30 Days)
1.1M
596.1K
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
3.14%
EPS Growth
51.40
647.37
EPS
N/A
0.08
Revenue
$6,941,000.00
$299,169,000.00
Revenue This Year
N/A
$8.42
Revenue Next Year
$1,127.34
$5.25
P/E Ratio
N/A
$408.63
Revenue Growth
N/A
9.20
52 Week Low
$8.67
$26.81
52 Week High
$30.06
$37.22

Technical Indicators

Market Signals
Indicator
IMNM
IVT
Relative Strength Index (RSI) 62.76 32.44
Support Level $18.72 $32.38
Resistance Level N/A $32.91
Average True Range (ATR) 1.51 0.58
MACD 0.15 -0.07
Stochastic Oscillator 66.25 18.38

Price Performance

Historical Comparison
IMNM
IVT

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About IVT InvenTrust Properties Corp.

InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.

Share on Social Networks: